Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary OT-101 PRESENTATION AT PHARMA FORUM 2020
AGOURA HILLS, Calif. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that on September 21, 2020 , Dr. Vuong Trieu , CEO of Mateon, will be presenting as Webinar “Trabedersen-Drug
View HTML
Toggle Summary FDA Granted Pediatric Disease Designation for OXi-4503
-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced
View HTML
Toggle Summary MATEON’S GLOBAL STUDY FOR ARTEMISININ INTERVENTION AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN INDIA.
AGOURA HILLS, Calif. , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its global study based on its ARTI-19 protocol for Artemisinin Intervention against COVID-19 has been
View HTML
Toggle Summary MATEON THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
AGOURA HILLS, Calif. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), a leading developer of TGF-β therapeutics, announced financial results for the second quarter ended June 30, 2020 . Unless otherwise stated, all comparisons are for the second quarter of 2020 compared to
View HTML
Toggle Summary MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL STUDY TO TEST ARTEMISININ AS A TREATMENT FOR COVID-19 IN INDIA
AGOURA HILLS, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, will be working together with Abiogenesis to initiate ARTI-19 randomized, controlled, multi-site India clinical study of Artemisinin against COVID-19.
View HTML
Toggle Summary Mateon Therapeutics Closes $2.0 Million Financing
AGOURA HILLS, Calif. , July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) announced the closing of the 1 st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc. (“EdgePoint”, a Delaware Corporation and a division of Mateon).  JH Darbie & Co.,
View HTML
Toggle Summary Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19
AGOURA HILLS, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research
View HTML
Toggle Summary Mateon Therapeutics to fund observational studies of Artemisinin in developing countries
AGOURA HILLS, Calif. , July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the
View HTML
Toggle Summary Company expands its management team to accelerate the commercialization and development of OT-101 for COVID-19
-   Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics (MATN). Agoura Hills, California , July 09, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) , a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-β inhibitor with the potential for multiple
View HTML
Toggle Summary Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine
Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19 Agoura Hills, California , July 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) , a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-β inhibitor with the
View HTML